Benzene Ring In Acid Moiety Patents (Class 514/555)
  • Patent number: 9844526
    Abstract: Methods of increasing the plasma concentration of resveratrol in a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Gateway Health Alliances, Inc.
    Inventors: Shil Kothari, Gary Troxel
  • Patent number: 9782375
    Abstract: Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 10, 2017
    Inventors: Shil Kothari, Gary Troxel
  • Patent number: 9447114
    Abstract: This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 20, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440983
    Abstract: This invention relates to novel Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440973
    Abstract: This invention relates to novel Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440972
    Abstract: This invention relates to novel Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9382187
    Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 5, 2016
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 9359301
    Abstract: The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: June 7, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Daniel Rueher, Heinz Stadler, Eric Vieira
  • Patent number: 9278134
    Abstract: Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: March 8, 2016
    Assignees: The Board of Trustees of the University of Alabama, Monash University, Queen's University Belfast
    Inventors: Robin D. Rogers, Daniel T. Daly, Douglas MacFarlane, Janet L. Scott, Kenneth R. Seddon, Gabriela Gurau, Katharina Bica, Jelena Turanjanin, Pamela M. Dean
  • Patent number: 9149497
    Abstract: Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 6, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Robert Cafferata
  • Patent number: 8952059
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 10, 2015
    Assignee: Sigma-Tau Industrie Faramceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Patent number: 8932626
    Abstract: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: January 13, 2015
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Akiko Katayama, Katsuyuki Inoo
  • Patent number: 8865769
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 21, 2014
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Publication number: 20140303250
    Abstract: A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH value ranging from 9 to 9.5 to the obtained solution, which do not cause sensory irritation to the oral cavity especially to the back of the mouth and throat, when swallowed.
    Type: Application
    Filed: November 14, 2012
    Publication date: October 9, 2014
    Inventors: Alberto Moretto, Alessandra De Lazzari, Lucia Dicorato
  • Patent number: 8765811
    Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 1, 2014
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Banavara L. Mylari, Frank C. Sciavolino
  • Publication number: 20140178480
    Abstract: Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 26, 2014
    Inventors: Clifford Riley King, David W. Bristol, Michael L. English
  • Patent number: 8741886
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: June 3, 2014
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 8729122
    Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: May 20, 2014
    Assignee: Valent BioSciences Corporation
    Inventors: Maria Pilar Herrero, Warren E. Shafer
  • Publication number: 20140128466
    Abstract: Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease.
    Type: Application
    Filed: July 20, 2012
    Publication date: May 8, 2014
    Applicant: VENANTIUS LIMITED
    Inventors: Neil Frankish, Helen Sheridan
  • Patent number: 8691873
    Abstract: The invention provides a method of treating leukemia using a pharmaceutical composition containing bis-benzyl lipoate, triethanolamine, and a pharmaceutically acceptable diluent, where the bis-benzyl lipoate and triethanolamine form an ion pair.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: April 8, 2014
    Assignee: Cornerstone Pharmaceuticals, Inc.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Patent number: 8669288
    Abstract: The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: March 11, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ahmed F. Abdel-Magid, Steven J. Mehrman, Armin Roessler
  • Patent number: 8586633
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: November 19, 2013
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Publication number: 20130295009
    Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof;
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Torbjorn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT
  • Publication number: 20130289112
    Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.
    Type: Application
    Filed: March 21, 2011
    Publication date: October 31, 2013
    Applicant: TIANJIN CHASESUN PHARMACEUTICAL CO., LTD
    Inventors: Jiang Zheng, Xinchuan Zheng, Xin Liu, Hong Zhou, Ning Wang, Hongwei Cao, Yan Li, Yongling Lu, Kecen Zhao, Jingcheng Yang, Yang Yang, Yuanfeng Zhu, Guo Wei, Min Huang
  • Patent number: 8569366
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: October 29, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Patent number: 8501759
    Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: August 6, 2013
    Assignee: Fournier Laboratories Ireland Limited
    Inventor: Eric Bruckert
  • Patent number: 8487002
    Abstract: A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: July 16, 2013
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Vincent Lenaerts, Patricia Laure Ouadji-Njiki, Johnatan Bacon, Rachid Ouzerourou, Sonia Gervais, Miloud Rahmouni, Damon Smith
  • Publication number: 20130178529
    Abstract: The present invention provides an improved ibuprofen lysine pharmaceutical composition and a process for preparing the same.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 11, 2013
    Applicant: Recordati Rare Diseases Inc.
    Inventor: Recordati Rare Diseases Inc.
  • Patent number: 8481596
    Abstract: The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: July 9, 2013
    Assignee: Lupin Limited
    Inventors: Gurvinder Pal Singh, Dabeer Rauf Karnalkar, Hemraj Mahadeorao Lande, Girij Pal Singh
  • Publication number: 20130137769
    Abstract: Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 30, 2013
    Inventors: Ketan Rajnibhai Patel, Milan Rajnibhai Patel
  • Publication number: 20130123287
    Abstract: Providing a novel control agent for soft rot and a novel control method for the same. A compound having no antibacterial activity against Erwinia carotovora but having a control activity against fungi on soil surface, specifically containing, as the active ingredient, a fungicide comprising any of a strobilurin compound such as azoxystrobin and kresoxim-methyl, an azole compound such as triflumizol, cyazofamid, amisulbrom, and thiophanate-methyl, a carboxamide compound such as penthiopyrad and boscalid, a sulfonamide compound such as flusulfamide, an organic chlorine compound such as chlorothalonil, a dicarboximide compound such as pro-cymidone and iprodione, a phenylpyrrole compound such as fludioxonil, an anilinopyrimidine compound such as mepanipyrim, and a guanidine compound such as iminoctadine is the control agent for plant soft rot, which is applied to plant cultivation soil.
    Type: Application
    Filed: July 21, 2011
    Publication date: May 16, 2013
    Applicant: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Koji Sugimoto, Hiroyuki Hayashi
  • Patent number: 8435497
    Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 7, 2013
    Assignee: Takeda GmbH
    Inventors: Klaus Dietzel, Helgert Mueller
  • Publication number: 20130089617
    Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.
    Type: Application
    Filed: October 11, 2012
    Publication date: April 11, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Chiesi Farmaceutici S.p.A.
  • Publication number: 20130078284
    Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 28, 2013
    Inventors: Tzuchi R. Ju, Claudia M. Davila, Yi Gao, Linda E. Gustavson, David LeBlond, Tong Zhu
  • Publication number: 20130065957
    Abstract: The present invention relates to a compound of diclofenac-tramadol salt in 1:1 ratio and a pharmaceutical formulation comprising such compound. The present invention also relates to a method for treating a patient with moderate to moderately severe pain. The method comprises: identifying a patient suffering from moderate to moderately severe pain with pain intensity scale of 5-9, and administering to said patient the diclofenac-tramadol salt, in an effective amount. The method is particularly useful in treating postoperative pain after Cesarean, postoperative pain after non-Cesarean surgeries, cancer pain, osteoarthritis pain, or rheumatoid arthritis pain.
    Type: Application
    Filed: November 1, 2012
    Publication date: March 14, 2013
    Applicants: CARLSBAD TECHNOLOGY, INC., YUNG SHIN PHARM. IND. CO., LTD.
    Inventors: Yung Shin Pharm. Ind. Co., Ltd., Carlsbad Technology, Inc.
  • Publication number: 20130064870
    Abstract: The dry powder inhalation composition comprising (1) salmeterol xinafoate having mean particle size in range of 2.0?-6? microns and a tapped density in the range of 0.20 g·cm?3 to 0.45 g·cm?3 and (2) optionally, one or more other active ingredients and pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 13, 2011
    Publication date: March 14, 2013
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Subhas Bhowmick, Prashant Kane, Ganesh S, Tarun Patel, Swapnil Chudiwal
  • Patent number: 8367726
    Abstract: The present invention relates to an acid salt of tolterodine with superior stabililty and useful as a transdermal drug delivery system. More specifically, the present invention relates to a novel acid salt of tolterodine with superior stabililty to the conventional acid salts of tolterodine, which is useful as a pharmaceutical composition for the treatment of overactive bladder and can be formulated into a transdermal drug delivery system.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 5, 2013
    Assignee: SK Chemicals Co., Ltd.
    Inventors: Yong Youn Hwang, Nam Ho Kim, Won Jae Choi, Yong Han Kim
  • Publication number: 20130030033
    Abstract: This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A1, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 31, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Patent number: 8349893
    Abstract: This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A1, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: January 8, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Patrizio Mattei
  • Publication number: 20120316238
    Abstract: The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient.
    Type: Application
    Filed: September 21, 2011
    Publication date: December 13, 2012
    Applicant: Lupin Limited
    Inventors: Gurvinder Pal SINGH, Dabeer Rauf Karnalkar, Hemraj Mahadeorao Lande, Girij Pal Singh
  • Patent number: 8263593
    Abstract: Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed, for treating baldness, glaucoma or inflammatory bowel diseases.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: September 11, 2012
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Patent number: 8236984
    Abstract: The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds. wherein X, Y, R1, R2, R3, R4, m, n, p, q, and the linker are as defined herein.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: August 7, 2012
    Assignee: Pentraxin Therapeutics Ltd.
    Inventors: Mark Brian Pepys, Steven Victor Ley, Angus John Morrison, Vittorio Bellotti, Simon Kolstoe, Martin Smith
  • Patent number: 8232265
    Abstract: Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: July 31, 2012
    Assignee: Board of Trustees of the University of Alabama
    Inventors: Robin D. Rogers, Daniel T. Daly, Richard P. Swatloski, Whitney L. Hough, James Hilliard Davis, Jr., Marcin Smiglak, Juliusz Pernak, Scott K. Spear
  • Publication number: 20120171262
    Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
    Type: Application
    Filed: March 15, 2012
    Publication date: July 5, 2012
    Inventors: Tzuchi R. Ju, Claudia M. Davila, Yi Gao, Linda E. Gustavson, David LeBlond, Tong Zhu
  • Publication number: 20120172227
    Abstract: A 5-aminolevulinic acid salt which is useful in fields of microorganisms, fermentation, animals, medicaments, plants and the like; a process for producing the same; a medical composition comprising the same; and a plant activator composition comprising the same.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 5, 2012
    Applicant: COSMO OIL CO., LTD
    Inventors: Naohisa TACHIYA, Seiji NISHIKAWA, Mai HIGO, Tohru TANAKA, Masahiro ISHIZUKA, Hideki OKADA
  • Publication number: 20120157526
    Abstract: Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.
    Type: Application
    Filed: June 8, 2010
    Publication date: June 21, 2012
    Applicant: UCL Business PLC
    Inventors: Rajiv Jalan, Keith Anderson
  • Patent number: 8173707
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 8, 2012
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Publication number: 20120101159
    Abstract: The present invention refers to an ibuprofen lysinate-based pharmaceutical composition in the form of oral suspension and to the preparation procedure thereof.
    Type: Application
    Filed: April 27, 2010
    Publication date: April 26, 2012
    Applicant: Laboratorio De Aplicaciones Farmacodinamicas, S.A.
    Inventor: Maite Tarre Perez
  • Patent number: 8133916
    Abstract: The present invention is a method for increasing serotonin activity in mammary glands such that involution of milk secretion of the same mammary glands occurs. The present invention further is a composition that can be implanted, or infused into the mammary glands to cause involution of milk secretion.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: March 13, 2012
    Assignee: Amelgo, LLC
    Inventors: Nelson D. Horseman, Robert J. Collier, Aaron M. Marshall, Laura Hernandez Baumgard
  • Publication number: 20120058965
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Application
    Filed: June 17, 2011
    Publication date: March 8, 2012
    Inventors: William A. GODDARD, III, Mark MENNA, Stephen PANDOL, Ravinder ABROL